The National Institutes of Health’s new Vaccinology and Immunology Center, whose opening was marked on October 5, will investigate health problems following infections as well as following vaccination, according to NIH leaders speaking after the launch and reported by STAT on October 26. That is broader than the framing at the opening event, which centred on patients reporting vaccine injuries and was attended by Health Secretary Robert F. Kennedy Jr. A senior NIH official told STAT that for people with long Covid symptoms it can be hard to separate whether symptoms began because of a vaccine or an infection, since many people have experienced both, and that the immunological mechanisms, and therefore the treatments, are similar.
The NIH’s own statement, issued October 19 by Director Jay Bhattacharya and NIAID Acting Director John H. Powers III, sets the remit in the same combined terms. The center will bring together patients, physician-scientists and laboratory researchers to evaluate participants’ illnesses and the immunology of how vaccination or infection may have contributed, identify why some people experience symptoms and what makes them vulnerable, and explore treatments, connecting participants with ongoing care closer to home where appropriate. The statement notes that Congress recognised in 1986, in creating the National Vaccine Injury Compensation Program, that vaccines benefit many people and can also cause adverse effects in some recipients, and that long Covid has since shown that many infections cause long-term symptoms often indistinguishable from adverse events after vaccination.
What is not yet public is the operating detail: the NIH statement does not set out a referral route, an enrolment target or a start date for the study, and those gaps have already drawn criticism from the board overseeing the NIH research hospital, according to weekend commentary on the program. Until a protocol is published, the center is a stated remit in search of a study design.
For the sector, the significance is evidentiary rather than commercial. A federal research program that studies post-vaccination and post-infection syndromes under one protocol will shape the safety literature that vaccine makers, regulators and courts cite for years, whichever way its findings point.